SK Biopharmaceuticals Co., Ltd. (KRX: 326030)

SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 19, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	7,995,783	7,862,650	5,646,385	7,612,048	13,234,939	-
Market Cap Growth	20.65%	39.25%	-25.82%	-42.49%	-	-
Enterprise Value	7,932,915	7,807,605	5,442,304	7,267,516	12,840,764	-
Last Close Price	102100.00	100400.00	72100.00	97200.00	169000.00	-
PE Ratio	139.34	-	-	117.39	-	-
PS Ratio	15.64	22.16	22.94	18.18	509.06	-
PB Ratio	23.66	24.50	17.84	17.14	34.91	-
P/TBV Ratio	25.07	29.59	18.86	17.90	36.83	-
EV/Sales Ratio	15.51	22.00	22.11	17.36	493.89	-
EV/EBITDA Ratio	130.39	-	-	68.18	-	-
EV/EBIT Ratio	182.87	-	-	76.53	-	-
Debt / Equity Ratio	0.48	0.55	0.49	0.04	0.05	-8.37
Debt / EBITDA Ratio	2.01	-	-	0.15	-	-
Asset Turnover	0.67	0.51	0.38	0.73	0.08	1.06
Inventory Turnover	0.46	0.35	0.53	0.60	0.13	0.15
Quick Ratio	1.20	1.47	2.28	2.64	5.67	0.58
Current Ratio	1.63	2.02	2.99	3.18	6.16	0.68
Return on Equity (ROE)	14.32%	-11.10%	-36.66%	15.75%	-135.18%	-313.65%
Return on Assets (ROA)	5.77%	-3.38%	-12.53%	10.38%	-46.83%	-42.23%
Return on Capital (ROIC)	8.42%	-4.83%	-17.57%	13.84%	-60.65%	-64.06%
Earnings Yield	0.72%	-0.42%	-2.47%	0.85%	-1.87%	-
FCF Yield	0.23%	-1.23%	-2.92%	-1.28%	-1.68%	-
Buyback Yield / Dilution	-	-	-9.12%	-10.41%	-4.42%
Total Shareholder Return	-	-	-9.12%	-10.41%	-4.42%

Source: S&P Capital IQ. Standard template. Financial Sources.